A-485

• CAT Number: I013011
• CAS Number: 1889279-16-6
• Molecular Formula: C₂₅H₂₄F₄N₄O₅
• Molecular Weight: 536.48
• Purity: ≥95%
• Target: Epigenetic Reader Domain
• Solubility: DMSO: ≥ 250 mg/mL
• IUPAC Name: N-[(4-fluorophenyl)methyl]-2-[(3R)-6-(methylcarbamoylamino)-2',4'-dioxospiro[1,2-dihydroindene-3,5'-1,3-oxazolidine]-3'-yl]-N-[(2S)-1,1,1-trifluoropropan-2-yl]acetamide
• InChI: InChI=1S/C25H24F4N4O5/c1-14(25(27,28)29)32(12-15-3-5-17(26)6-4-15)20(34)13-33-21(35)24(38-23(33)37)10-9-16-11-18(7-8-19(16)24)31-22(36)30-2/h3-8,11,14H,9-10,12-13H2,1-2H3,(H2,30,31,36)/t14-,24+/m0/s1
• InChIKey: VRVJKILQRBSEAG-LFPIHBKWSA-N
• SMILES: C[C@@H](C(F)(F)F)N(CC1=CC=C(C=C1)F)C(=O)CN2C(=O)[C@]3(CCC4=C3C=CC(=C4)NC(=O)NC)OC2=O

A-485（Cat No.:I013011）is a potent and selective inhibitor of CBP/EP300, two key transcriptional coactivators involved in gene expression regulation. By targeting these proteins, A-485 disrupts transcriptional programs related to cancer cell growth and survival, making it a promising compound in cancer research. Its mechanism of action involves blocking histone acetyltransferase activity, thus inhibiting the transcription of oncogenes. A-485 has shown efficacy in preclinical models, particularly in prostate cancer studies, and is a valuable tool for exploring epigenetic therapies in oncology research.

Reference

[1]. Lasko LM, et al. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. Nature. 2017 Oct 5;550(7674):128-132.